AAPL327.74+1.15 (+0.35%) ▲|ABBV256.05+2.67 (+1.05%) ▲|ABT99.68-1.98 (-1.95%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.81+4.09 (+3.18%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.15+28.25 (+2.46%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|AAPL327.74+1.15 (+0.35%) ▲|ABBV256.05+2.67 (+1.05%) ▲|ABT99.68-1.98 (-1.95%) ▼|ACN140.86-3.87 (-2.67%) ▼|ADBE227.16-7.58 (-3.23%) ▼|AMAT564.55+38.85 (+7.39%) ▲|AMD544.43+40.86 (+8.11%) ▲|AMGN366.24+2.07 (+0.57%) ▲|AMT163.39-3.67 (-2.20%) ▼|AMZN247.55-2.44 (-0.98%) ▼|AVGO386.50+8.34 (+2.21%) ▲|AXP350.79-1.14 (-0.32%) ▼|BA204.80-4.68 (-2.23%) ▼|BAC61.22+0.80 (+1.32%) ▲|BKNG179.40-0.05 (-0.03%) ▼|BLK1,038.24-15.87 (-1.51%) ▼|BMY60.93+0.77 (+1.28%) ▲|BNY158.89+1.96 (+1.25%) ▲|BRK-B489.65-1.60 (-0.33%) ▼|C132.81+4.09 (+3.18%) ▲|CAT889.97+25.67 (+2.97%) ▲|CL90.50-1.43 (-1.56%) ▼|CMCSA23.81+0.03 (+0.13%) ▲|COF206.22-0.55 (-0.27%) ▼|COP117.50+1.82 (+1.57%) ▲|COST929.22-6.58 (-0.70%) ▼|CRM170.06-3.73 (-2.15%) ▼|CSCO112.18+1.48 (+1.34%) ▲|CVS110.60+2.99 (+2.78%) ▲|CVX191.07+1.36 (+0.72%) ▲|DE586.88+0.88 (+0.15%) ▲|DHR179.01-22.10 (-10.99%) ▼|DIS96.14-0.27 (-0.28%) ▼|DUK125.91+0.06 (+0.05%) ▲|EMR139.26+2.68 (+1.96%) ▲|FDX315.19+8.97 (+2.93%) ▲|GD367.73-2.87 (-0.77%) ▼|GE340.70-0.60 (-0.18%) ▼|GEV1,078.81-0.37 (-0.03%) ▼|GILD130.28-2.93 (-2.20%) ▼|GM79.52+3.72 (+4.91%) ▲|GOOG346.19-5.18 (-1.47%) ▼|GOOGL347.15-4.84 (-1.38%) ▼|GS1,085.56+30.53 (+2.89%) ▲|HD331.60-1.44 (-0.43%) ▼|HON229.86+3.68 (+1.63%) ▲|IBM210.50-2.50 (-1.17%) ▼|INTC105.45+8.39 (+8.64%) ▲|INTU289.92-3.90 (-1.33%) ▼|ISRG350.06-3.11 (-0.88%) ▼|JNJ250.61+1.79 (+0.72%) ▲|JPM345.23+6.36 (+1.88%) ▲|KO81.97-0.15 (-0.18%) ▼|LIN505.03-7.02 (-1.37%) ▼|LLY1,175.15+28.25 (+2.46%) ▲|LMT507.09-2.45 (-0.48%) ▼|LOW203.51-1.20 (-0.59%) ▼|LRCX322.00+15.24 (+4.97%) ▲|MA538.30-9.14 (-1.67%) ▼|MCD263.91-3.73 (-1.39%) ▼|MDLZ59.86-0.41 (-0.68%) ▼|MDT82.35-0.94 (-1.13%) ▼|META643.81-2.04 (-0.32%) ▼|MMM170.76+11.65 (+7.32%) ▲|MO72.99-1.67 (-2.24%) ▼|MRK126.26+1.86 (+1.50%) ▲|MS216.40+5.46 (+2.59%) ▲|MSFT397.75-4.54 (-1.13%) ▼|MU970.82+105.36 (+12.17%) ▲|NEE87.93-0.07 (-0.08%) ▼|NFLX68.67+1.07 (+1.58%) ▲|NKE42.96-0.51 (-1.17%) ▼|NOW102.06-2.64 (-2.52%) ▼|NVDA207.29+4.01 (+1.97%) ▲|ORCL127.05+5.67 (+4.67%) ▲|PEP135.00-0.46 (-0.34%) ▼|PFE24.94+0.19 (+0.77%) ▲|PG148.10-1.03 (-0.69%) ▼|PLTR132.66-2.19 (-1.62%) ▼|PM188.04-4.68 (-2.43%) ▼|QCOM173.50+3.18 (+1.87%) ▲|RTX193.67-0.77 (-0.40%) ▼|SBUX104.45-0.36 (-0.34%) ▼|SCHW99.96-2.58 (-2.52%) ▼|SO93.85-0.61 (-0.65%) ▼|SPG226.79-1.40 (-0.61%) ▼|T22.26+0.31 (+1.41%) ▲|TMO523.46-2.77 (-0.53%) ▼|TMUS190.77-4.87 (-2.49%) ▼|TSLA378.93+9.36 (+2.53%) ▲|TXN291.30+7.23 (+2.55%) ▲|UBER71.55-0.62 (-0.86%) ▼|UNH436.35+14.80 (+3.51%) ▲|UNP293.13-3.12 (-1.05%) ▼|UPS116.34+3.19 (+2.82%) ▲|USB63.71+0.57 (+0.90%) ▲|V355.82-4.75 (-1.32%) ▼|VZ43.78+0.28 (+0.64%) ▲|WFC87.74+1.41 (+1.63%) ▲|WMT110.39-1.81 (-1.61%) ▼|XOM151.71+3.35 (+2.26%) ▲|
27.4 C
New York
Tuesday, July 21, 2026

Tag: Johnson & Johnson

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

Vascarta Announces Addition of Dr. Janet Loesberg to Leadership Team

Janet Loesberg, PhRMA/Biotech veteran, brings medical and launch expertise. SUMMIT, N.J., July 28, 2025 /PRNewswire/ -- Vascarta Inc. today announced the addition of Janet Loesberg,...

Biosurgery Market worth US$21.59 Billion by 2030 with 6.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...

Biosurgery Market worth US$21.59 Billion by 2030 with 6.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

B7-H4 Targeting Therapies Market Growth Set to Accelerate Across the 7MM During the Study Period (2025-2040) with Advances in Immunotherapy | DelveInsight

The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025...

Johnson & Johnson showcases latest advancements in Alzheimer’s research at AAIC 2025

Early data from robust Autonomy Phase 2b posdinemab trial demonstrate Company's leadership in multimodal biomarkers and early detection New findings highlight the central role of...

Ipsen announces changes to its Executive Committee

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch

Veteran pharma operator co-founded Ategenos to tackle the global $1 trillion crisis of medication non-adherence CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsJohnson & Johnson